Liquidia’s (LQDA) “Market Perform” Rating Reiterated at Lifesci Capital

Liquidia (NASDAQ:LQDA)‘s stock had its “market perform” rating restated by research analysts at Lifesci Capital in a report issued on Wednesday,Benzinga reports. They presently have a $90.00 price objective on the stock. Lifesci Capital’s price target would indicate a potential upside of 13.82% from the company’s previous close.

Other equities analysts have also issued reports about the company. Needham & Company LLC raised their price target on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Stephens set a $130.00 price objective on Liquidia in a research report on Friday, July 24th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 target price on shares of Liquidia in a research note on Monday, May 11th. Wells Fargo & Company upped their price target on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $90.00.

Liquidia Trading Down 10.2%

NASDAQ LQDA traded down $8.98 during trading on Wednesday, hitting $79.07. 3,040,638 shares of the company’s stock traded hands, compared to its average volume of 1,774,534. The stock has a fifty day moving average of $77.76 and a two-hundred day moving average of $54.51. Liquidia has a 12-month low of $21.15 and a 12-month high of $93.61. The firm has a market cap of $7.03 billion, a P/E ratio of 564.83 and a beta of 0.58. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the prior year, the firm posted ($0.49) EPS. The firm’s quarterly revenue was up 1842.1% on a year-over-year basis. As a group, sell-side analysts expect that Liquidia will post 3.02 EPS for the current year.

Insider Transactions at Liquidia

In other Liquidia news, Director Stephen M. Bloch sold 242,269 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $70.43, for a total value of $17,063,005.67. Following the completion of the sale, the director directly owned 1,176,184 shares in the company, valued at $82,838,639.12. This trade represents a 17.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Paul B. Manning sold 200,000 shares of Liquidia stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $63.91, for a total value of $12,782,000.00. Following the sale, the director directly owned 716,311 shares in the company, valued at approximately $45,779,436.01. The trade was a 21.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 1,781,861 shares of company stock valued at $124,407,112. 25.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Liquidia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new position in Liquidia in the second quarter worth $29,694,000. Handelsbanken Fonder AB bought a new stake in shares of Liquidia during the 2nd quarter valued at $1,993,000. Fulcrum Equity Management bought a new stake in shares of Liquidia during the 2nd quarter valued at $399,000. Fluent Financial LLC purchased a new stake in shares of Liquidia in the 2nd quarter worth about $287,000. Finally, FNY Investment Advisers LLC purchased a new position in Liquidia during the 2nd quarter valued at about $1,395,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales accelerated. Net product sales reached approximately $170.4 million in the second quarter, up 31% from the first quarter. Liquidia reported roughly 5,900 unique prescriptions and more than 5,000 patients treated since the product launched in June 2025. Liquidia Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability and cash generation improved. Liquidia posted $171.7 million in revenue, $74.7 million in net income and $96.3 million in adjusted EBITDA, marking its fourth consecutive quarter of increasing profitability. Cash and equivalents rose to approximately $284.2 million from $190.7 million at the end of 2025. Liquidia Q2 Net Income Reaches $74.7 Million As YUTREPIA Sales Rise
• Positive Sentiment: Management maintained its long-term growth outlook. Liquidia reaffirmed its target of more than $1 billion in net revenue in 2027 and is advancing 10 clinical studies involving YUTREPIA and the L606 inhaled treprostinil program.
• Neutral Sentiment: Institutional interest remains mixed but generally supportive. Recent filings showed major investors including BlackRock and State Street adding shares, although some funds reduced their positions.
• Negative Sentiment: Adjusted expectations contributed to the selloff. Diluted EPS of $0.74 was slightly below the approximately $0.76 analyst consensus cited by several reports, despite revenue exceeding expectations. Another estimate source placed consensus at $0.70, highlighting differences among analyst forecasts. Liquidia shares fall after second-quarter earnings miss despite revenue growth
• Negative Sentiment: Spending is increasing. Research and development expenses rose to $17.2 million from $6.0 million a year earlier as Liquidia funds the Phase 3 L606 program. The company’s elevated valuation also leaves less room for disappointing results.
• Negative Sentiment: Insider selling is a potential overhang. Reported insider activity over the past six months consisted overwhelmingly of sales, including transactions by senior executives, with only one reported purchase.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).